OK, this was my layman's understanding. It looks like leronlimab was willing to accept patients who were SICKER than the RLFTF trial. Plus the fact that our trial started earlier than theirs when ICUs were just starting to figure out treatment protocol and thus death rates were higher.
Thank you!